Paragon Care FY26 slides: normalized growth strong despite $38M charge

Paragon Care reported FY26 underlying revenue of $3.7B (+1.8% reported; +6.7% normalized) and underlying EBITDA of $97.2M (+7.4% normalized), but statutory results deteriorated to a $16.0M net loss due to a $38M Infinity Group debt provision. Despite operating cash flow jumping 89.4% to $65.8M, net debt rose 31.3% to $284.1M (2.5x underlying EBITDA), keeping leverage at the top end of management’s target range. Management highlighted completion of its 3-2-1 integration and delivered $5.3M synergies, while also planning an FY27 employee share trust and a share buyback to address undervaluation; however, FY27 guidance remains withheld due to uncertain fuel costs and ongoing integration/infinity recovery risk.

Analysis

The market is treating this as a quality-of-earnings problem, not a growth story. The operative question is whether the cash conversion improvement is durable enough to justify a re-rate, because the business now sits close to the top of its leverage range and any working-capital slippage would quickly absorb the apparent progress. The announced buyback is supportive, but only if management can fund it without starving integration and inventory discipline; otherwise it becomes a signal of confidence that competes with balance-sheet repair.

The better businesses inside the group are the higher-touch logistics and clinical manufacturing pieces, which should command a higher multiple than the legacy wholesale/distribution base. That creates a second-order effect: if the mix shift continues, the market may eventually award a sum-of-parts premium, but if freight, FX, or inventory normalization reverses, these same segments will look like operating leverage traps rather than margin expanders. The debt provision also raises a broader credit-quality flag: if counterparty stress was isolated, the stock is cheap; if it is repeatable, statutory losses will keep suppressing valuation and likely limit M&A flexibility.

Near term, the catalyst path is mostly execution-based over the next 1-3 months: buyback cadence, first evidence of FY27 contract ramp, and whether fuel costs stay benign. Over 6-18 months, the key is whether reduced capex translates into sustained free cash flow and de-levering. The contrarian view is that the stock may already discount too much bad news at the lows, but the setup is not clean enough to call it a value trap break until cash flow stays positive without relying on normalization add-backs.

Key Decisions for Investors

• PGC: Do not chase the post-results bounce; use any rally back toward the prior support/resistance zone as a fade opportunity over the next 2-6 weeks, with downside risk to the recent low if the market decides the buyback is not cash-backed.
• PGC: Initiate only a small starter long after the company shows one clean quarter of buyback execution plus working-capital discipline; upside is a multiple rerate if net debt trends below 2.3x EBITDA, but the thesis breaks if leverage stays pinned at ~2.5x.
• Pair trade: long CSL / short PGC as a relative-quality healthcare expression for 1-3 months if you want sector exposure; CSL offers cleaner earnings quality while PGC remains exposed to accounting noise, integration risk, and balance-sheet sensitivity.
• Watch item, not a trade: if operating cash flow in the next half-year falls materially below the recent run-rate or if fuel/inventory costs re-accelerate, abandon the buyback-led re-rating thesis and expect further multiple compression.